CD274 and cancer: Targeting this axis has become a success story in cancer immunotherapy, exhibiting durable responses for numerous advanced stage cancers, which has led to further research into the use of PD-1/PD-L1 inhibitors to treat aggressive cancers like SCLC [65,66,67].